Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 2 days ago
- 1 min read
01/04/2026
Alkermes announced initiation of Phase 3 Brilliance studies evaluating alixorexton for NT1 and NT2 (Ref)
Alkermes announced the initiation of the Phase 3 Brilliance studies program, which evaluated the safety and efficacy of alixorexton (ALKS 2680; selective OX2R agonist) for the treatment of adult patients with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2)
The Brilliance studies program consisted of three Phase 3 studies evaluating once-daily and split-dose regimens of alixorexton:
Brilliance NT1 studies: Study 302/ NCT07455383 and study 304 is not yet started
Brilliance NT2 studies: Study 303/ NCT07502443
